



Financial Tear Sheet

CORPORATE PROFILE

Motif Bio is a clinical stage biopharmaceutical company developing novel antibiotics to treat patients with serious and life-threatening infections caused by multi-drug resistant bacteria.

PRIMARY IR CONTACT

E-mail: ir@motifbio.com

STOCK DETAILS

MTFB (ADS)	
Exchange	NASDAQ GS (US Dollar)
Price	\$9.10
Change (%)	▼ 0.24 (2.57%)
Volume	7,634
52 Week Low	\$5.36
Market Cap	\$
Rolling EPS	0.00
PE Ratio	0
Shares Outstanding	

Data as of December 15, 2017 2:59 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.



RECENT NEWS & UPCOMING EVENTS

November 15, 2017

There are currently no events scheduled.

Motif Bio secures up to US\$20 million debt financing

October 6, 2017

Motif Bio Presents New Pre-Clinical Data for Iclaprim at

IDWeek 2017™

October 4, 2017

Motif Bio Announces Positive Topline Results for iclaprim in

the REVIVE-2 Phase 3 Study

SEC FILINGS

Filing Date	Form
December 14, 2017	6-K
December 13, 2017	F-3
November 15, 2017	6-K
October 6, 2017	6-K